| Title： | Expert consensus on off-label use of endocrine therapy in the treatment of breast cancer |
| Edition： | Original |
| Classification： | Experts consensus |
| Field： | Diagnosis and Treatment |
| Countries and regions： | China |
| Guidelines users： | Clinical physicians at all levels (including doctor, pharmacist and other relevant fields) |
| Evidence classification method： | CSCO grading system |
| Development unit： | Chinese Society of Clinical Oncology Breast Cancer |
| Registration time: | 2023-04-05 |
| Registration number： | PREPARE-2023CN242 |
| Purpose of the guideline: | Endocrine therapy is one of the important means of breast cancer treatment. With the launch of some new endocrine therapy drugs and the continuous updating of clinical research data, as well as issues related to the accessibility of drugs, the approved indications, applicable groups, dosage and route of administration of breast cancer endocrine therapy drugs are not sufficient to meet the real-world treatment needs of breast cancer endocrine therapy. Off-label drug use is an objective clinical practice. The aim of this consensus is to make an evidence-based evaluation of the use of over-specified drugs in breast cancer endocrine therapy based on the content of domestic and foreign drug registration, consensus guidelines, clinical studies and other evidence-based medical evidence, and then for the expert group to form a recommendation on the use of over-specified drugs in breast cancer endocrine therapy, so as to provide clinicians with a rational basis for the use of drugs and further regulate the off-label drug use in breast cancer endocrine therapy. The expert group will then form recommendations, providing clinicians with a rational basis for their use and further standardizing the clinical application of off-label drug use in breast cancer. |
Latest registration
